Last quarter (Q2 2024), MEI Pharma's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q2, MEI Pharma's net income was $-11.06M. See MEI Pharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Jun 23	Jun 22	Jun 21	Jun 20	Jun 19
Total Revenue	$ 72.65M	$ 48.82M	$ 40.70M	$ 34.80M	$ 27.76M	$ 4.92M
Cost of Revenue	-	-	-	$ -1.41M	$ 2.67M	$ 4.26M
Gross Profit	$ 72.65M	$ 48.82M	$ 40.70M	$ 33.39M	$ 25.09M	$ 652.00K
Operating Expense	$ 56.77M	$ 85.58M	$ 116.18M	$ 93.81M	$ 50.78M	$ 46.90M
Operating Income	$ 15.88M	$ -36.76M	$ -75.48M	$ -60.42M	$ -25.70M	$ -46.24M
Net Non Operating Interest Income Expense	-	-	-	-	$ 1.40M	$ 1.79M
Other Income Expense	$ -3.96M	$ -4.93M	$ -21.03M	$ -19.12M	$ -22.87M	$ 27.63M
Pretax Income	$ 19.84M	$ -31.84M	$ -54.45M	$ -41.31M	$ -47.17M	$ -16.82M
Tax Provision	$ -187.00K	$ -187.00K	$ -191.00K	$ 8.00K	$ 1.00K	$ 1.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ 4.41M	$ -31.84M	$ -54.45M	$ -110.02M	$ -47.17M	$ -16.82M
Basic EPS	$ 4.48	$ -4.78	$ -8.80	$ -9.00	$ -0.51	$ -0.24
Diluted EPS	$ 4.48	$ -4.78	$ -10.00	$ -13.60	$ -0.51	$ -0.75
Basic Average Shares	$ 19.99M	$ 6.66M	$ 6.22M	$ 5.63M	$ 91.08M	$ 71.14M
Diluted Average Shares	$ 19.99M	$ 6.66M	$ 6.26M	$ 5.72M	$ 91.08M	$ 72.39M
Dividend Per Share	$ 1.75	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 56.77M	$ 85.58M	$ 116.18M	$ 92.40M	$ 53.45M	$ 51.16M
Net Income From Continuing And Discontinued Operation	$ 19.84M	$ -31.84M	$ -54.45M	$ -41.31M	$ -47.17M	$ -16.82M
Normalized Income	$ 37.24M	$ -29.43M	-	-	$ -24.30M	$ -36.99M
Interest Expense	-	-	-	-	-	-
EBIT	$ 19.84M	$ -31.84M	$ -54.45M	$ -41.31M	$ -25.70M	$ -46.24M
EBITDA	$ 35.55M	$ -31.45M	$ -54.13M	$ -41.02M	$ -25.59M	$ -46.16M

Currency in USD

MEI Pharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing